Median durations of response in the overall population were 5.7 months in the combination arm and 4.2 months in the monotherapy arm. Compared with patients receiving cetuximab alone, the cetuximab/irinotecan patients experienced a significantly longer median time to disease progression.
Continue reading " Treating Colorectal Cancer: TREATMENT part 3 "
Capecitabine. An alternative strategy to modulating 5-FU-based chemotherapy has been established through the development of oral fluoropyrimidine analogues. Capecit-abine (Xeloda, Roche), a fluoropyrimidine carbamate with antineoplastic activity, is an orally administered systemic prodrug of 5′-deoxy-5-fluorouridine, which is converted in the body to 5-FU.
Continue reading " Treating Colorectal Cancer: TREATMENT part 2 "
Surgery for Colon Cancer
Surgical removal of the involved segment of colon (colec-tomy), along with its blood supply and regional lymph nodes, is the primary therapy for colon cancer. The conventional and accepted treatment for curative resection of colon cancer is laparotomy with hemicolectomy for right-sided or left-sided lesions .
The technique of colon resection through an [...]
A study was conducted to investigate the prognostic factors for colorectal cancer patients in order to improve future treat-ment. Patients who had undergone curative resection (n = 842) were divided into three groups according to age: young (40 years or younger), middle-aged (41 to 64 years), and older (65 years or above). Univariate survival and [...]
Continue reading " Treating Colorectal Cancer: PROGNOSTIC FACTORS "
INTRODUCTION
Colorectal cancer is a significant contributor to morbidity and mortality in the U.S., making this disease the second leading cause of cancer deaths overall. In 2002, more than 56,000 lining of the bowel. Some become malignant over time. Most evidence suggests that adenomas are precursors for a substantial proportion of colorectal cancers. This has prompted [...]
Education
Healthcare Providers. Healthcare providers, including primary care physicians, have an essential role to play in encouraging more Hispanic patients to be screened and treated for kidney disease and its risk factors. Physicians also have a responsibility to improve their referral of patients with kidney disease for appropriate treatment, such as dialysis, without delay.
Continue reading " Kidney Disease in the Hispanic Population: DIRECTIONS FOR IMPROVEMENT "
Economic factors contribute to a large proportion of the disparities seen between Hispanics and the general U.S. population in the management of ESRD and its risk factors. In particular, lack of health insurance represents a major barrier to healthcare. Data from the Health and Retirement Survey revealed extremely low levels of insurance coverage among Hispanics, [...]
Continue reading " Kidney Disease in the Hispanic Population: ACCESS TO MEDICAL CARE "
